{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:35:48Z","timestamp":1793799348701,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02187-9","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:51:56Z","timestamp":1745974316000},"page":"957-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Catumaxomab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"8","key":"2187_CR1","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","volume":"98","author":"P Ruf","year":"2001","unstructured":"Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526\u201334.","journal-title":"Blood"},{"issue":"2","key":"2187_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261\u20136.","journal-title":"Br J Cancer"},{"key":"2187_CR3","unstructured":"European Medicines Agency. Catumaxomab (Korjuny\u00ae): summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/korjuny. Accessed 28 Mar 2025."},{"issue":"3","key":"2187_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","volume":"97","author":"P Ruf","year":"2007","unstructured":"Ruf P, Gires O, J\u00e4ger M, et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315\u201321.","journal-title":"Br J Cancer"},{"issue":"4","key":"2187_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.21037\/apm-23-554","volume":"13","author":"T Ikegami","year":"2024","unstructured":"Ikegami T, Ishiki H, Kadono T, et al. Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment. Ann Palliat Med. 2024;13(4):842\u201357.","journal-title":"Ann Palliat Med."},{"issue":"19","key":"2187_CR6","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1158\/1078-0432.CCR-05-0043","volume":"11","author":"K Passebosc-Faure","year":"2005","unstructured":"Passebosc-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res. 2005;11(19):6862\u20137.","journal-title":"Clin Cancer Res"},{"key":"2187_CR7","unstructured":"Lindis Biotech and Pharmanovia. Lindis Biotech and Pharmanovia announce European marketing authorisation approval for a first-in-class treatment [media release]. 14 Feb 2025. https:\/\/pharmanovia.com."},{"key":"2187_CR8","unstructured":"European Medicines Agency. Catumaxomab (Korjuny\u00ae): European Public Assessment Report. 2004. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/korjuny. Accessed 28 Mar 2025."},{"issue":"Suppl 2","key":"2187_CR9","doi-asserted-by":"publisher","first-page":"S1160","DOI":"10.1016\/j.annonc.2024.08.2096","volume":"35","author":"AA Antoniewicz","year":"2024","unstructured":"Antoniewicz AA, Albert F, Wessels F, et al. Trifunctional anti-EpCAM\/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): interim analysis of a phase I study [abstract no. 2010P]. Ann Oncol. 2024;35(Suppl 2):S1160.","journal-title":"Ann Oncol"},{"issue":"9","key":"2187_CR10","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s00262-021-02930-7","volume":"70","author":"P Ruf","year":"2021","unstructured":"Ruf P, Bauer HW, Schoberth A, et al. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunol Immunother. 2021;70(9):2727\u201335.","journal-title":"Cancer Immunol Immunother"},{"issue":"Suppl 16","key":"2187_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16102","volume":"40","author":"C Qi","year":"2022","unstructured":"Qi C, Wu S, Kim I-H, et al. Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. J Clin Oncol. 2022;40(Suppl 16): e16102.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2187_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41416-018-0150-6","volume":"119","author":"M Kn\u00f6dler","year":"2018","unstructured":"Kn\u00f6dler M, K\u00f6rfer J, Kunzmann V, et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM \u00d7 anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018;119(3):296\u2013302.","journal-title":"Br J Cancer"},{"issue":"8","key":"2187_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bjc.2014.443","volume":"111","author":"J Sehouli","year":"2014","unstructured":"Sehouli J, Reinthaller A, Marth C, et al. Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. Br J Cancer. 2014;111(8):1519\u201325.","journal-title":"Br J Cancer"},{"issue":"1","key":"2187_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2011.06.004","volume":"123","author":"K Baumann","year":"2011","unstructured":"Baumann K, Pfisterer J, Wimberger P, et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol. 2011;123(1):27\u201332.","journal-title":"Gynecol Oncol"},{"key":"2187_CR15","unstructured":"Fresenius Biotech GmbH. European Commission grants Orphan Drug Designation for the Removab\u00ae antibody to treat gastric cancer [media release]. 21 Nov 2006. http:\/\/www.fresenius.de."},{"key":"2187_CR16","unstructured":"Fresenius Biotech GmbH. Fresenius receives Orphan Drug Designation for antibody Removab\u00ae to treat patients with ovarian cancer [media release]. 19 Mar 2004. http:\/\/www.fresenius.de."},{"key":"2187_CR17","unstructured":"United States Food and Drug Administration. Orphan drug product designation database. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/. Accessed 26 Mar 2025."},{"key":"2187_CR18","unstructured":"Pharmanovia. Pharmanovia signs novel biologic in-licensing agreement with Lindis Biotech to commercialise catumaxomab for treatment of rare condition, malignant ascites [media release]. 19 Nov 2024. http:\/\/www.pharmanovia.com."},{"key":"2187_CR19","unstructured":"Lindis Biotech. Lindis Biotech announces publication of patient data highlighting the potential of trifunctional antibody catumaxomab for treatment of non-muscle-invasive bladder cancer in peer-reviewed journal [media release]. 1 Jun 2021. http:\/\/www.lindisbiotech.com."},{"key":"2187_CR20","unstructured":"Swedish Orphan Biovitrum. Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab\u00ae [media release]. 21 Jan 2011. http:\/\/www.fresenius.com."},{"key":"2187_CR21","unstructured":"Fresenius Biotech GmbH. Fresenius sells biotechnology business [media release]. 28 Jun 2013. http:\/\/www.fresenius.de."},{"issue":"10","key":"2187_CR22","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2165\/11209040-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Catumaxomab: in malignant ascites. Drugs. 2012;72(10):1399\u2013410.","journal-title":"Drugs"},{"issue":"1","key":"2187_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","volume":"72","author":"M J\u00e4ger","year":"2012","unstructured":"J\u00e4ger M, Schoberth A, Ruf P, et al. Immunomonitoring results of a phase II\/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM \u00d7 anti-CD3). Cancer Res. 2012;72(1):24\u201332.","journal-title":"Cancer Res"},{"issue":"9","key":"2187_CR24","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127(9):2209\u201321.","journal-title":"Int J Cancer"},{"issue":"2","key":"2187_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ygyno.2015.06.003","volume":"138","author":"M Fossati","year":"2015","unstructured":"Fossati M, Buzzonetti A, Monego G, et al. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM\u00d7anti-CD3). Gynecol Oncol. 2015;138(2):343\u201351.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2187_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","volume":"69","author":"P Ruf","year":"2010","unstructured":"Ruf P, Kluge M, J\u00e4ger M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69(6):617\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"13","key":"2187_CR27","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study. Clin Cancer Res. 2007;13(13):3899\u2013905.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2187_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","volume":"24","author":"JS Berek","year":"2014","unstructured":"Berek JS, Edwards RP, Parker LP, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014;24(9):1583\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"2187_CR29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/ijc.26258","volume":"130","author":"MG Ott","year":"2012","unstructured":"Ott MG, Marm\u00e9 F, Moldenhauer G, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II\/III study in patients with malignant ascites. Int J Cancer. 2012;130(9):2195\u2013203.","journal-title":"Int J Cancer"},{"issue":"12","key":"2187_CR30","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1158\/1078-0432.CCR-13-2351","volume":"20","author":"MM Heiss","year":"2014","unstructured":"Heiss MM, Str\u00f6hlein MA, Bokemeyer C, et al. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II\/III study. Clin Cancer Res. 2014;20(12):3348\u201357.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2187_CR31","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, Gilet H, Gonschior AK, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979\u201385.","journal-title":"Ann Oncol"},{"issue":"8","key":"2187_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-014-0076-7","volume":"31","author":"J Sehouli","year":"2014","unstructured":"Sehouli J, Pietzner K, Wimberger P, et al. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol. 2014;31(8):76.","journal-title":"Med Oncol"},{"issue":"12","key":"2187_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12032-014-0308-x","volume":"31","author":"K Pietzner","year":"2014","unstructured":"Pietzner K, Vergote I, Santoro A, et al. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Med Oncol. 2014;31(12):308.","journal-title":"Med Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02187-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02187-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:55:17Z","timestamp":1750679717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02187-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2187"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02187-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"7 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}